Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desferrioxamine + silymarin is a combination therapy consisting of desferrioxamine (also known as deferoxamine), an iron-chelating agent, and silymarin, a flavonoid complex extracted from Silybum marianum (milk thistle) with antioxidant and hepatoprotective properties. Desferrioxamine binds free iron in the body to facilitate its excretion, thereby reducing iron overload commonly seen in patients requiring frequent blood transfusions such as those with beta-thalassemia. Silymarin acts primarily as an antioxidant and may provide additional protection against organ damage from iron overload by stabilizing cell membranes and scavenging free radicals. Clinical studies suggest that the combination is well tolerated and may be more effective than desferrioxamine alone in reducing serum ferritin levels in patients with transfusion-dependent thalassemia[1][3][5]. The combination has also been studied for its effects on organ-specific iron deposition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desferrioxamine + silymarin.